Skip Navigation

Vaccine Safety Bibliography - February 2014

1.   Early estimates of seasonal influenza vaccine effectiveness - United States, January 2013. MMWR Morb Mortal Wkly Rep. 2013 Jan 18;62:32-5. 

2.   Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR Morb Mortal Wkly Rep. 2013 Jan 25; 62:52-4.

3.   Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec. 2013 Jan 4; 88(1):1-16.

4.  Progress in immunization information systems - United States, 2011. MMWR Morb Mortal Wkly Rep. 2013 Jan 25; 62:48-51.

5.   Recommendation of WHO Strategic Advisory Group of Experts (SAGE) on Immunization. Pediatrics. 2013 Jan; 131(1):e343.

6.   Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Am J  Transplant. 2013 Jan; 13(1):232-5.

7.   Vaccination against H1N1 looks safer than influenza during pregnancy. BMJ. 2013 Jan 23; 346:f375.

8.   Advisory Committee on Immunization Practices†. Recommended Adult Immunization  Schedule: United States, 2013*. Ann Intern Med. 2013 Jan 29. [Epub ahead of print].

9.   Aikawa N, Campos L, Goldenstein-Schainberg C, Saad C, Ribeiro A, Bueno C, Precioso A, Timenetsky M, Silva C, Bonfá E. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol. 2013; 42(1):34-40.

10.  Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J. Herd protection by a bivalent-killed-whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print].  

11.  Ambrose CS, Toback SL. Improved Timing of Availability and Administration of Influenza Vaccine Through the US Vaccines for Children Program From 2007 to 2011. Clin Pediatr (Phila). 2013 Jan 8. [Epub ahead of print].

12.  Ambrose CS, Wu X. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine. 2013 Jan 30; 31(6):857-60.

13.  Anderson EJ, Shippee DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S, Cuyugan MG, Lee SY, Simons YM, Yogev R, Noskin GA. Indirect Protection of Adults From Rotavirus by Pediatric Rotavirus Vaccination. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print].

14.  Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: Evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother. 2013 Jan 7; 9(3). [Epub ahead of print].

15.  Ansaldi F, de Florentiis D, Canepa P, Ceravolo A, Rappazzo E, Iudici R, Martini M, Botti G, Orsi A, Icardi G, Durando P. Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: Rationale and perspectives for PCV13 implementation. Hum Vaccin Immunother. 2013 Jan 4; 9(3). [Epub ahead of print].

16.  Atchison C, Zvoc M, Balakrishnan R. The Evaluation of a Standardized Call/Recall System for Childhood Immunizations in Wandsworth, England. J Community Health. 2013 Jan 26. [Epub ahead of print].

17.  Bakir M, Standaert B, Turel O, Bilge ZE, Postma M. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine. 2013 Jan 30; 31(6):979-86.

18.  Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D,  Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013 Jan; 207(1):115-24.

19.  Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of Monovalent A(H1N1)pdm09 and 2010-11 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-11 Season. J Infect Dis. 2013 Jan 22. [Epub ahead of print].

20.  Batista-Duharte A, Lastre M, Pérez O. [Immunological adjuvants. Determinant factors in the efficacy-toxicity ratio of the contemporary vaccines.]. Enferm Infecc Microbiol Clin. 2013 Jan 16. [Epub ahead of print].

21.  Bednarczyk RA, Duvall S, Meldrum MD, Flynn MK, Santilli LA, Easton DE, Sharma P, Blog DS, Zansky SM, McNutt LA, Birkhead GS. Evaluating the Most Effective Distribution Strategies to Assure Administration of Pandemic H1N1 Influenza Vaccine to New York State Children and Adolescents: Evaluation Using the New York State Immunization Information System. J Public Health Manag Pract. 2013 Jan 7. [Epub ahead of print].

22.  Bergfors E, Lundmark K, Nyström Kronander U. A child with a long-standing, intensely itching subcutaneous nodule on a thigh: an uncommon (?) reaction to commonly used vaccines. BMJ Case Rep. 2013 Jan 24; 2013.

23.   Betsch C, Schmid P. [Does fear affect the willingness to be vaccinated? : The influence of cognitive and affective aspects of risk perception during outbreaks]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jan; 56(1):124-30.

24.  Betsch C, Renkewitz F, Haase N. Effect of Narrative Reports about Vaccine Adverse Events and Bias-Awareness Disclaimers on Vaccine Decisions: A Simulation  of an Online Patient Social Network. Med Decis Making. 2013 Jan; 33(1):14-25.

25.  Bhatta DN. Involvement of males in antenatal care, birth preparedness, exclusive breast feeding and immunizations for children in Kathmandu, Nepal. BMC  Pregnancy Childbirth. 2013 Jan 16;13:14.

26.  Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N, Seitz S, Azarkh Y, Mahalingam R, Gilden D, Cohrs RJ. Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. J Virol. 2013 Jan; 87(1):415-21.

27.  Birnbaum MS, Jacobs ET, Ralston-King J, Ernst KC. Correlates of high vaccination exemption rates among kindergartens. Vaccine. 2013 Jan 21; 31(5):750-6.

28.  Bivas-Benita M, Gillard GO, Bar L, White KA, Webby RJ, Hovav AH, Letvin NL. Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity. Mucosal Immunol. 2013 Jan; 6(1):156-66.

29.  Björkman I, Sanner MA. The Swedish A(H1N1) vaccination campaign-Why did not all Swedes take the vaccination? Health Policy. 2013 Jan; 109(1):63-70.

30.  Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013 Jan 7; 9(3). [Epub ahead of print].

31.  Boršo D, Löbermann M, Fritzsche C, Hemmer C, Führer A, Zettl U, Reisinger EC. [Vaccinations in patients with immunodeficiency or immunosuppressive therapy]. Dtsch Med Wochenschr. 2013 Jan; 138(4):145-51.

32.  Bresalier M. Fighting flu: military pathology, vaccines, and the conflicted identity of the 1918-19 pandemic in Britain. J Hist Med Allied Sci. 2013 Jan;68(1):87-128.

33.  Brisson M, Drolet M, Malagón T. Inequalities in Human Papillomavirus (HPV)-Associated Cancers: Implications for the Success of HPV Vaccination. J Natl Cancer Inst. 2013 Jan 7. [Epub ahead of print].

34.  Bryan M, Guyach S, Norris KA. Biolistic DNA vaccination against Trypanosoma infection. Methods Mol Biol. 2013; 940:305-15.

35.  Burchill MA, Tamburini BA, Pennock ND, White JT, Kurche JS, Kedl RM. T cell vaccinology: Exploring the known unknowns. Vaccine. 2013 Jan 2;31(2):297-305. 

36.  Caini S, Beck NS, Yacouba H, Maiga I, Chaibou I, Hinsa I, Adakal A, Issoufou  A, Kim SH, Pezzoli L. From Agadez to Zinder: estimating coverage of the MenAfriVacTM conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012. Vaccine. 2013 Jan 19. [Epub ahead of print].

37.  Callaway E. Vaccine switch urged for polio endgame. Nature. 2013 Jan 17;493(7432):285.

38.  Camacho AI, Irache JM, Gamazo C. Recent progress towards development of a Shigella vaccine. Expert Rev Vaccines. 2013 Jan; 12(1):43-55.

39.  Caplan AL. Morality of influenza Vaccine Mandates. Clin Ther. 2013 Jan 8. [Epub ahead of print]

40.  Carrico RM, Wiemken T, Westhusing K, Christensen D, McKinney WP. Health care  personnel immunization programs: An assessment of knowledge and practice among infection preventionists in US health care facilities. Am J Infect Control. 2013 Jan 10. [Epub ahead of print]

41.  Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013 Jan 16; 9(5). [Epub ahead of print].

42.  Cenoz MG, Martínez-Artola V, Guevara M, Ezpeleta C, Barricarte A, Castilla J. Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Hum Vaccin Immunother.  2013 Jan 16; 9(5). [Epub ahead of print].

43.  Ceyhan M, Celik M, Demir ET, Gurbuz V, Aycan AE, Unal S. Acquisition of meningococcal serogroup w-135 carriage in Turkish hajj pilgrims who had received  the quadrivalent meningococcal polysaccharide vaccine. Clin Vaccine Immunol. 2013 Jan; 20(1):66-8.

44.  Chang YC, Huang N, Chen LS, Hsu SW, Chou YJ. Factors affecting repeated influenza vaccination among older people in Taiwan. Vaccine. 2013 Jan 2; 31(2):410-6.  

45.  Chen D, Zehrung D. Desirable attributes of vaccines for deployment in low-resource settings. J Pharm Sci. 2013 Jan; 102(1):29-33.

46.  Chen MC, Huang SF, Lai KY, Ling MH. Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials. 2013 Jan 28. [Epub ahead of print].

47.  Cheong AT, Tong SF, Khoo EM. How useful is a history of rubella vaccination for determination of disease susceptibility? a cross-sectional study at a public funded health clinic in Malaysia. BMC Fam Pract. 2013 Jan 31; 14(1):19. [Epub ahead of print].

48.  Chiu PJ, Chen CH, Chih YC. Effectiveness of the influenza vaccination program for the elderly in Taiwan. Vaccine. 2013 Jan 11; 31(4):632-8.

49.  Chouhy D, D'Andrea RM, Iglesias M, Messina A, Ivancovich JJ, Cerda B, Galimberti D, Bottai H, Giri AA. Prevalence of human papillomavirus infection in  Argentinean women attending two different hospitals prior to the implementation of the National Vaccination Program. J Med Virol. 2013 Jan 7. [Epub ahead of print]

50.  Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine. 2013 Jan 7; 31(3):518-23.

51.  Ciruela P, Martínez A, Izquierdo C, Hernández S, Broner S, Muñoz-Almagro C, Domínguez A, Of Catalonia Study Group TM. Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines. Hum Vaccin Immunother. 2013 Jan 9; 9(3). [Epub ahead of print].

52.  COMMITTEE ON INFECTIOUS DISEASES. Recommended Childhood and Adolescent Immunization Schedule--United States, 2013. Pediatrics. 2013 Jan 28. [Epub ahead  of print].

53.  Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: Insights and future perspectives. Int J Pharm. 2013 Jan 2;440(1):27-38.

54.  Covolo L, Mascaretti S, Caruana A, Orizio G, Caimi L, Gelatti U. How has the  flu virus infected the Web? 2010 influenza and vaccine information available on the Internet. BMC Public Health. 2013 Jan 29;13(1):83. [Epub ahead of print].

55. Crawford CM, Grazko MB, Raymond WR 4th, Rivers BA, Munson PD. Retrobulbar optic neuritis and live attenuated influenza vaccine. J Pediatr Ophthalmol Strabismus. 2013 Jan 1;50(1):61.

56.  Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013 Jan 4; 15(1):R1. [Epub ahead of print].

57.  Daniel M, Gautam S, Scrivener TA, Meller C, Levin B, Curotta J. What effect has pneumococcal vaccination had on acute mastoiditis? J Laryngol Otol. 2013 Jan;127 Suppl 1:S30-4.

58.  de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013 Jan 8. [Epub ahead of print].

59.  Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R. Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin  Biol Ther. 2013 Jan; 13(1):121-35.

60.  Denny L, Kim J. European cost-effectiveness analysis of cervical screening strategies for women not vaccinated for HPV: in many scenarios primary HPV screening is preferable to primary cytology screening in women aged over 30 years. Evid Based Nurs. 2013 Jan; 16(1):8-9.

61.  Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013 Jan 11;31(4):685-90.

62.  Desai R, Cortese MM, Meltzer MI, Shankar M, Tate JE, Yen C, Patel MM, Parashar UD. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J. 2013 Jan; 32(1):1-7.

63.  Desai SP, Lu B, Szent-Gyorgyi LE, Bogdanova AA, Turchin A, Weinblatt M, Coblyn J, Greenberg JO, Kachalia A, Solomon DH. Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial. Arthritis Rheum. 2013 Jan; 65(1):39-47.

64.  Dias WO, van der Ark AA, Sakauchi MA, Kubrusly FS, Prestes AF, Borges MM, Furuyama N, Horton DS, Quintilio W, Antoniazi M, Kuipers B, van der Zeijst BA, Raw I. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother. 2013 Jan 4;9(2). [Epub ahead of print].

65.  Diazgranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013 Jan 30;31(6):861-6.

66.  Dicko A, Santara G, Mahamar A, Sidibe Y, Barry A, Dicko Y, Diallo A, Dolo A,  Doumbo O, Shafi F, François N, Strezova A, Borys D, Schuerman L. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccin Immunother. 2013 Jan 4; 9(2). [Epub ahead of print].

67.  Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, Mayoral JM, Martín V, Quintana JM, González-Candelas F, Galán JC, Tamames S, Castro A, Baricot M, Garín O, García JJ, Moraga F, Pumarola T; for the CIBERESP Cases and Controls in Pandemic Influenza Working Group, Spain. Benefit of Conjugate Pneumococcal Vaccination in Preventing Influenza Hospitalization in  Children: A Case-Control Study. Pediatr Infect Dis J. 2013 Jan 18. [Epub ahead of print].

68.  Drees M, Tambourelli B, Denstman A, Zhang W, Zent R, McGraw P, Ehrenthal DB.  Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-2011 influenza season. Vaccine. 2013 Jan 2;31(2):362-6.

69.  Dreyfus C. [Towards a universal vaccine against flu?]. Med Sci (Paris). 2013  Jan;29(1):22-5.

70.  Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: State of the evidence. Hum Vaccin Immunother. 2013 Jan 16;9(5). [Epub ahead of print].

71.  Duraisingham SS, Rouphael N, Cavanagh MM, Nakaya HI, Goronzy JJ, Pulendran B. Systems biology of vaccination in the elderly. Curr Top Microbiol Immunol. 2013; 363:117-42.

72.  Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial. J Infect Dis. 2013 Jan 31. [Epub ahead of print].

73.  Edwards KM, Booy R. Effects of exercise on vaccine-induced immune responses.  Hum Vaccin Immunother. 2013 Jan 14;9(4). [Epub ahead of print].

74.  Eisenberg DF, Gu T, Krishnarajah G. Adherence to rotavirus vaccination quality measures in a commercially insured population. Hum Vaccin Immunother. 2013 Jan 4;9(2). [Epub ahead of print]

75.  Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ. Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. J Immunol. 2013 Feb 1; 190(3):1135-47.

76.  Erlich P, Sansonetti PJ. [Acute intestinal infections: Current and upcoming vaccines]. Presse Med. 2013 Jan; 42(1):93-101.

77.   Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes. Clin Infect Dis. 2013 Jan; 56(2):267-70.

78.  Fahlbusch M, Wesselmann U, Lehmann P. [Herpes zoster after varicella-zoster vaccination.]. Hautarzt. 2013 Jan 30. [Epub ahead of print].  

79.  Farkouh R, Klok R, Roberts C, Mack A, Strutton D. Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2013 Jan 7;31(3):439-41.

80.  Flannery B, Samad S, de Moraes JC, Tate JE, Danovaro-Holliday MC, de Oliveira LH, Rainey JJ. Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program. Vaccine. 2013 Jan 10. [Epub ahead of print].

81.  Freitas DR, Moura E, Araújo G, Cardoso A, Scheidt P, Ferraz E, Madalosso G, Chen RT, Hatch DL. Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. Vaccine. 2013 Jan 30; 31(6):950-4. 

82.  Fu C, Xu J, He Q, Li Z, Liu F. Seasonal influenza vaccine effectiveness in children during 2010-2011 season: A case-cohort study. Hum Vaccin Immunother. 2013 Jan 16;9(5). [Epub ahead of print]

83.  Gans HA, Yasukawa LL, Sung P, Sullivan B, Dehovitz R, Audet S, Beeler J, Arvin AM. Measles humoral and cell-mediated immunity in children aged 5-10 years  after primary measles immunization administered at 6 or 9 months of age. J Infect Dis. 2013 Feb; 207(4):574-82.

84.  Garattini L, van de Vooren K. The Bayesian Model on Human Papillomavirus Vaccination in Italy Lacks Transparency. Med Care. 2013 Jan 25. [Epub ahead of print].

85.  Garcia CR, Manzi F, Tediosi F, Hoffman SL, James ER. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine. 2013 Jan 2;31(2):380-6.

86.  Gasparini R, Bonanni P, Amicizia D, Bella A, Donatelli I, Cristina ML, Panatto D, Lai PL. Influenza epidemiology in Italy two years after the 2009-2010  pandemic: Need to improve vaccination coverage. Hum Vaccin Immunother. 2013 Jan 4;9(3). [Epub ahead of print].

87.  Gershon AA. Varicella zoster vaccines and their implications for development of HSV vaccines. Virology. 2013 Jan 5; 435(1):29-36.

88.  Ghanem A, Healey R, Adly FG. Current trends in separation of plasmid DNA vaccines: A review. Anal Chim Acta. 2013 Jan 14;760:1-15.

89.  Ghosh SK, Roy Chowdhury R. Synthetic adjuvants for vaccine formulations: phytol derivatives. Expert Opin Drug Deliv. 2013 Jan 8. [Epub ahead of print].

90.  Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Dramé M, Schwarz TF. An assessment of prime-boost vaccination schedules with AS03(A) -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respi Viruses. 2013 Jan; 7(1):55-65.

91.  Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman  SP, Kpamegan E, Boddapati S, Piedra PA. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 7;31(3):524-32.

92.  Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Fallert Junecko BA, Reinhart TA, Kolls J, Randall TD, Connell TD, Khader SA. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 2013 Jan 9. [Epub ahead of print]

93.  Gottvall M, Tydén T, Larsson M, Stenhammar C, Höglund AT. Informed Consent for HPV Vaccination: A Relational Approach. Health Care Anal. 2013 Jan 1. [Epub ahead of print]

94.  Gowda C, Schaffer SE, Kopec K, Markel A, Dempsey AF. A pilot study on the effects of individually tailored education for MMR vaccine-hesitant parents on MMR vaccination intention. Hum Vaccin Immunother. 2013 Jan 4; 9(2). [Epub ahead of print].

95.  Grant L, Watt J, Moulton L, Weatherholtz R, Reid R, Santosham M, O'Brien K. Lack of Non-Specific Protection Against All-Cause, Non-Rotavirus Gastroenteritis  by Vaccination with Orally Administered Rotavirus Vaccine. J Pediatr Gastroenterol Nutr. 2013 Jan 21. [Epub ahead of print]

96.  Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, van Loveren H, Løvik M, Nygaard UC. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J Immunotoxicol. 2013 Jan 25. [Epub ahead of print].

97.  Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.  Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013 Jan 21;31(5):770-6.

98.  Grimaldi-Bensouda L, Aubrun E, Leighton P, Benichou J, Rossignol M, Abenhaim L; the PGRx Study Group. Agreement between patients' self-report and medical records for vaccination: the PGRx database. Pharmacoepidemiol Drug Saf. 2013 Jan  14. [Epub ahead of print].

99.  Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013 Jan 3. [Epub ahead of print].

100. Grogg SE. Update on Advisory Committee on Immunization's Practices (ACIP) Vaccine Recommendations, October 2012. J Am Osteopath Assoc. 2013 Jan;113(1):13-5.

101. Grund S, Wichmann O, Mertens T, Hengel H. [Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jan;56(1):76-86.

102. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan. 2013 Jan;28(1):51-61.

103. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza:  a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013 Jan 28. [Epub ahead of print]

104. Gutierrez B Jr, Leung A, Jones KT, Smith P, Silverman R, Frank I, Leader AE. Acceptability of the human papillomavirus vaccine among urban adolescent males. Am J Mens Health. 2013 Jan; 7(1):27-36.

105. Hak E, Shea KM, Jick SS. Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: A nested case-control study using the GPRD. Vaccine. 2013 Jan 25. [Epub ahead of print].

106. Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W. Near Complete Elimination of the Seven Valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee. Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print].

107. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013 Jan; 12(1):57-70.

108. Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre  CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; on behalf of the Danish Pneumococcal Surveillance Collaborating Group. Pediatric Invasive Pneumococcal Disease Caused by Vaccine Serotypes following the Introduction of Conjugate Vaccination in Denmark. PLoS One. 2013;8(1):e51460.

109. Harjaningrum AT, Kartasasmita C, Orne-Gliemann J, Jutand MA, Goujon N, Koeck JL. A qualitative study on knowledge, perceptions, and attitudes of mothers and health care providers toward pneumococcal conjugate vaccine in Bandung, West Java, Indonesia. Vaccine. 2013 Jan 11. [Epub ahead of print].

110. He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB. Heterovariant Cross-Reactive B-Cell Responses Induced by the 2009 Pandemic Influenza Virus A Subtype H1N1 Vaccine. J Infect Dis. 2013 Jan;207(2):288-96.

111. Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M. Vaccination and Tick-borne Encephalitis, Central Europe. Emerg Infect Dis. 2013 Jan; 19(1):69-76.

112. Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact  of vaccination with meningococcal C conjugate vaccine. J Infect. 2013 Jan;66(1):48-56.

113. Hemming M, Räsänen S, Huhti L, Paloniemi M, Salminen M, Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr. 2013 Jan 30. [Epub ahead of print].

114. Hewett R, VanCuren A, Trocio L, Beaudrault S, Gund A, Luther M, Groom H. Rules and tools that improved vaccines for children vaccine-ordering practices in Oregon: a 2010 pilot project. J Public Health Manag Pract. 2013 Jan-Feb; 19(1):9-15.

115. Hirobe S, Okada N, Nakagawa S. Transcutaneous vaccines - current and emerging strategies. Expert Opin Drug Deliv. 2013 Jan 15. [Epub ahead of print].

116. Hirth JM, Tan A, Wilkinson GS, Berenson AB. Completion of the human papillomavirus (HPV) vaccine series among males with private insurance between 2006 and 2009. Vaccine. 2013 Jan 2. [Epub ahead of print].

117. Hoke CH Jr, Snyder CE Jr. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine. 2013 Jan 3. [Epub ahead of print].

118. Huijskens EG, Reimerink J, Mulder PG, van Beek J, Meijer A, de Bruin E, Friesema I, de Jong MD, Rimmelzwaan GF, Peeters MF, Rossen JW, Koopmans M. Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal  Vaccination. PLoS One. 2013;8(1):e54890.

119. Håberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, Skrondal A, Cappelen I, Engeland A, Aavitsland P, Madsen S, Buajordet I, Furu K,  Nafstad P, Vollset SE, Feiring B, Nøkleby H, Magnus P, Stoltenberg C. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med. 2013 Jan 24; 368(4):333-40.

120. Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J, Destefano F, Cheetham  TC, Jackson LA, Naleway AL, Glanz JM, Nordin JD, Belongia EA; for the Vaccine Safety Datalink. Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstet Gynecol. 2013 Jan;121(1):159-165.

121. Ishola DA Jr, Permalloo N, Cordery RJ, Anderson SR. Midwives' influenza vaccine uptake and their views on vaccination of pregnant women. J Public Health  (Oxf). 2013 Jan 30. [Epub ahead of print]

122. Jayasinghe S, Macartney K. Estimating rotavirus gastroenteritis hospitalisations by using hospital episode statistics before and after the introduction of rotavirus vaccine in Australia. Vaccine. 2013 Jan 30; 31(6):967-72.

123. Jin XW, Lipold L, Sikon A, Rome E. Human papillomavirus vaccine: Safe, effective, underused. Cleve Clin J Med. 2013 Jan; 80(1):49-60.

124. Jit M, Levin C, Brison M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med. 2013 Jan 30; 11(1):23. [Epub ahead of print].

125. Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother. 2013 Jan 28;9(5). [Epub ahead of print]

126. Joon Lee T, Hayes S, Cummings DM, Cao Q, Carpenter K, Heim L, Edwards H. Herpes zoster knowledge, prevalence, and vaccination rate by race. J Am Board Fam Med. 2013 Jan; 26(1):45-51.

127. Jounai N, Kobiyama K, Takeshita F, Ishii KJ. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol. 2012; 2:168.

128.  Kaboré NF, Poda GE, Barro M, Cessouma R, Héma A, Ouedraogo AS, Sawadogo AB,  Nacro B. Impact of vaccination on admissions for Haemophilus influenzae b meningitis from 2004 to 2008 in Bobo Dioulasso, Burkina Faso. Med Sante Trop. 2013 Jan 30. [Epub ahead of print]

129. Kakoulidou M, Ingelman-Sundberg H, Johansson E, Cagigi A, Farouk SE, Nilsson A, Johansen K. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine. 2013 Jan 11; 31(4):711-7.

130. Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, Corde N, Pouzet C,  Zimmermann G, Gurunathan S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013 Jan 2; 31(2):327-33.

131. Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, Stefanski H, Brunstein C, Cooley S, Miller JS, Blazar BR, Wagner JE, Verneris MR. A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2013 Jan;19(1):109-16.

132. Kasabi GS, Murhekar MV, Sandhya VK, Raghunandan R, Kiran SK, Channabasappa GH, Mehendale SM. Coverage and Effectiveness of Kyasanur Forest Disease (KFD) Vaccine in Karnataka, South India, 2005-10. PLoS Negl Trop Dis. 2013 Jan; 7(1):e2025.

133. Kazi AN. Measles epidemic exposes inadequate vaccination coverage in Pakistan. BMJ. 2013 Jan 14; 346:f245.

134. Kelly A, Jacobsson S, Hussain S, Olcén P, Mölling P. Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis. APMIS. 2013 Jan; 121(1):56-63.

135. Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ. Phase II Study of a Three-Dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-Month Hib-MenC-TT Booster in Healthy Infants. Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

136. Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, Lim JS. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months. Scand J Infect Dis. 2013 Jan 7. [Epub ahead of print].

137. King JC Jr, Lichenstein R, Magder LS. Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012. Vaccine. 2013 Jan 21; 31(5):839-44.

138. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics. 2013 Jan; 131(1):154-6.

139. Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM. One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135  and Y Tetanus Toxoid Conjugate Vaccine is Immunogenic in 9-12 Month Old Children. Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print].

140. Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR. Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden. Clin Ther. 2013 Jan 9. [Epub ahead of print].

141. Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013 Jan 11. [Epub ahead of print].

142. Kochhar S. Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon. Hum Vaccin Immunother. 2013 Jan 15; 9(4). [Epub ahead of print].

143. Koh HK, Gordon JL. Breaking through the status quo: improving influenza vaccination coverage among health-care personnel. Public Health Rep. 2013 Jan; 128(1):26-8.

144. Kos M, Locatelli I. Limitations of the study "Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults". Vaccine. 2013 Jan 23. [Epub ahead of print].

145. Košnik IG, Lah AK. A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia. Vaccine. 2013 Jan 21; 31(5):732-4.

146. Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol. 2013 Jan; 68(1):179-80.

147. Krypciak S, Mézière A, Belmin J, Herbaud S, Paillaud E. [Which vaccination and cardiovascular prevention in elderly?]. Presse Med. 2013 Feb;42(2):202-208.

148. Kuchar E, Nitsch-Osuch A, Zycinska K, Miskiewicz K, Szenborn L, Wardyn K. Influenza immunization rates in children and teenagers in Polish cities: conclusions from the 2009/2010 season. Adv Exp Med Biol. 2013; 755:243-9.

149. Ladd JM, Karkazis K, Magnus D. Parental refusal of vaccination and transplantation listing decisions: A nationwide survey. Pediatr Transplant. 2013 Jan 24. [Epub ahead of print].

150. Ladhani SN, Slack MP, Andrews NJ, Waight PA, Borrow R, Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and wales. Emerg Infect Dis. 2013 Jan; 19(1):61-8.

151. Laz TH, Rahman M, Berenson AB. Human papillomavirus vaccine uptake among 9-17 year old males in the United States: The National Health Interview Survey, 2010. Hum Vaccin Immunother. 2013 Jan 7;9(4). [Epub ahead of print].

152. Li M, Qiu YX. A review on current downstream bio-processing technology of vaccine products. Vaccine. 2013 Jan 9. [Epub ahead of print].

153. Lindley LL, Elkind JS, Landi SN, Brandt HM. Receipt of the human papillomavirus vaccine among female college students in the United States, 2009.  J Am Coll Health. 2013 Jan; 61(1):18-27.

154. Lindley MC. Billing Practices of Local Health Departments Providing 2009 Pandemic Influenza A (H1N1) Vaccine. J Public Health Manag Pract. 2013 Jan 28. [Epub ahead of print].

155. Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T,  Liang Z, Mao Q, Wang L, Dong C, Liao Y, Guo L, Yang E, Pu J, Yue L, Zhou Z, Li Q. Study of the Integrated Immune Response Induced by an Inactivated EV71 Vaccine. PLoS One. 2013;8(1):e54451.

156. Livingston KA, Jiang X, Stephensen CB. CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization. J Immunol Methods. 2013 Jan 11. [Epub ahead of print].

157. Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, Silva-Abuin JM. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013 Jan; 24(1):127-34.

158. Louik C, Chambers C, Jacobs D, Rice F, Johnson D, Mitchell AA. Influenza vaccine safety in pregnancy: can we identify exposures? Pharmacoepidemiol Drug Saf. 2013 Jan; 22(1):33-9.

159. Luke JL, McDonald L, Jude V, Chan KW, Cuellar NG. Clinical Practice Implications of Immunizations After Pediatric Bone Marrow Transplant: A Literature Review. J Pediatr Oncol Nurs. 2013 Jan; 30(1):7-17.

160. Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype  vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine. 2013 Jan 7. [Epub ahead of print].

161. Luyten J, Dorgali V, Hens N, Beutels P. Public preferences over efficiency, equity and autonomy in vaccination policy: An empirical study. Soc Sci Med. 2013 Jan;77:84-9.

162. López-Gigosos R, Campins M, Calvo MJ, Pérez-Hoyos S, Díez-Domingo J, Salleras L, Azuara MT, Martínez X, Bayas JM, Ramón Torrell JM, Pérez-Cobaleda MA, Núñez-Torrón ME, Gorgojo L, García-Rodríguez M, Díez-Díaz R, Armadans L, Sánchez-Fernández C, Mejías T, Masuet C, Pinilla R, Antón N, Segarra P. Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's  diarrhea: A prospective cohort study. Hum Vaccin Immunother. 2013 Jan 16; 9(3). [Epub ahead of print].

163. Mamma M, Spandidos DA. Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece.  Health Policy. 2013 Jan;109(1):71-7.

164. Marshall GS, Blatter M, Marchant C, Aris E, Mesaros N, Miller JM. Antibody Persistence for up to 5 Years After A Fourth Dose of Haemophilus influenzae Type  B and Neisseria Meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine  (Hibmency-TT) Given At 12-15 Months of Age. Pediatr Infect Dis J. 2013 Jan 21. [Epub ahead of print].

165. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013 Jan 24. [Epub ahead of print].

166. Martins RM, Maia MD, Farias RH, Camacho LA, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sá GR, Hokama DA, de Carvalho R, Freire RA, Filho EP, Leal MD, Homma A. 17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin  Immunother. 2013 Jan 30; 9(4). [Epub ahead of print]

167. Mastalerz-Migas A, Steciwko A, Brydak LB. Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol. 2013; 756:285-90.

168. McRee AL, Reiter PL, Pepper JK, Brewer NT. Correlates of comfort with alternative settings for HPV vaccine delivery. Hum Vaccin Immunother. 2013 Jan 4; 9(2). [Epub ahead of print]

169. Meharry PM, Colson ER, Grizas AP, Stiller R, Vázquez M. Reasons Why Women Accept or Reject the Trivalent Inactivated Influenza Vaccine (TIV) During Pregnancy. Matern Child Health J. 2013 Jan; 17(1):156-164.

170. Meregaglia M, Ferrara L, Melegaro A, Demicheli V. Parent "cocoon" immunization to prevent pertussis-related hospitalization in infants: The case of Piemonte in Italy. Vaccine. 2013 Jan 7. [Epub ahead of print].   

171. Metcalf CJ, Cohen C, Lessler J, McAnerney JM, Ntshoe GM, Puren A, Klepac P,  Tatem A, Grenfell BT, Bjørnstad ON. Implications of spatially heterogeneous vaccination coverage for the risk of congenital rubella syndrome in South Africa. J R Soc Interface. 2013 Jan 6;10(78):20120756.

172. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013 Jan; 40(1):28-31.

173. Milanovic M, Stojanovich L, Djokovic A, Kontic M, Gvozdenovic E. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med. 2013; 229(1):29-34.

174. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 1976  and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies  in Humans. J Infect Dis. 2013 Jan; 207(1):98-105.

175. Miyaji KT, Luiz AM, Lara AN, do Socorro Souza Chaves T, Piorelli RD, Lopes MH, Sartori AM. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more. Hum Vaccin Immunother. 2013 Jan 4; 9(2). [Epub ahead of print].

176. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013 Jan 23. [Epub ahead of print].

177. Mueller JE. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. Trop Med Int Health. 2013 Jan; 18(1):58-64.

178. Mukandavire Z, Smith DL, Morris JG Jr. Cholera in Haiti: Reproductive numbers and vaccination coverage estimates. Sci Rep. 2013;3:997.

179. Nagata T, Koide Y. Identification of T cell epitopes of Mycobacterium tuberculosis with biolistic DNA vaccination. Methods Mol Biol. 2013; 940:285-303. 

180. Nakayama T, Sawada A, Kubo H, Kaida A, Tanaka T, Shigemoto N, Komase K, Takeda M. Simple method to differentiate measles vaccine from wild-type strains using loop-mediated isothermal amplification (LAMP). Microbiol Immunol. 2013 Jan 22. [Epub ahead of print].

181. National Vaccine Advisory Committee. Strategies to achieve the healthy people 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the national vaccine advisory committee. Public Health Rep.  2013 Jan; 128(1):7-25.

182. Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine. J Infect  Dis. 2013 Jan;207(2):297-305.

183. Nelson JC, Yu O, Dominguez-Islas CP, Cook AJ, Peterson D, Greene SK, Yih WK, Daley MF, Jacobsen SJ, Klein NP, Weintraub ES, Broder KR, Jackson LA. Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. Am J Epidemiol. 2013 Jan 15; 177(2):131-41.

184. Nicoll A, Sprenger M. Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis. 2013 Jan; 13(1):7-9.

185. Nitsch-Osuch A, Kuchar E, Modrzejewska G, Pirogowicz I, Zycinska K, Wardyn K. Epidemiology of pertussis in an urban region of Poland: time for a booster for adolescents and adults. Adv Exp Med Biol. 2013;755:203-12.

186. O'Connor MB, Phelan MJ. Herpes zoster infection, vaccination and immunocompromised rheumatology patients. Rheumatol Int. 2013 Jan; 33(1):239-40.

187. O'Leary ST, Allison MA, Stokley S, Crane LA, Hurley LP, Beaty B, Kempe A. Physicians' confidence in vaccine safety studies. Prev Med. 2013 Jan 15. [Epub ahead of print].

188. O'Leary ST, Parashar UD, Crane LA, Allison MA, Stokley S, Beaty BL, Brtnikova M, Hurley LP, Kempe A. Adoption of rotavirus vaccine by u.s. Physicians: progress and challenges. Am J Prev Med. 2013 Jan; 44(1):56-62.

189. Omer SB, Zaman K, Roy E, Arifeen SE, Raqib R, Noory L, Seib K, Breiman RF, Steinhoff MC. Combined Effects of Antenatal Receipt of Influenza Vaccine by Mothers and Pneumococcal Conjugate Vaccine Receipt by Infants: Results from a Randomized, Blinded, Controlled Trial. J Infect Dis. 2013 Jan 31. [Epub ahead of print].

190. Opel DJ, Marcuse EK. The Enigma of Alternative Childhood Immunization Schedules: What Are the Questions? JAMA Pediatr. 2013 Jan 21:1-2. [Epub ahead of print].

191. Orenstein WA, Paulson JA, Brady MT, Cooper LZ, Seib K. Global vaccination recommendations and thimerosal. Pediatrics. 2013 Jan; 131(1):149-51.

192. Orsi A, Ansaldi F, de Florentiis D, Ceravolo A, Parodi V, Canepa P, Coppelli M, Icardi G, Durando P. Cross-protection against drifted influenza viruses: Options offered by adjuvanted and intradermal vaccines. Hum Vaccin Immunother. 2013 Jan 7; 9(3). [Epub ahead of print].

193. Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno  W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson  L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01. Malar J. 2013 Jan 23; 12(1):29. [Epub ahead of print].

194. Ouédraogo N, Kagoné M, Sié A, Becher H, Müller O. Immunization coverage in young children: A study nested into a health and demographic surveillance system in Burkina Faso. J Trop Pediatr. 2013 Jan 29. [Epub ahead of print].

195. Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther. 2013 Jan;13(1):11-33.

196. Pach A, Tabbusam G, Khan MI, Suhag Z, Hussain I, Hussain E, Mumtaz U, Haq IU, Tahir R, Mirani A, Yousafzai A, Sahastrabuddhe S, Ochiai RL, Soofi S, Clemens JD, Favorov MO, Bhutta ZA. Formative Research and Development of an Evidence-Based Communication Strategy: The Introduction of Vi Typhoid Fever Vaccine Among School-Aged Children in Karachi, Pakistan. J Health Commun. 2013 Jan 18. [Epub ahead of print].

197. Paine NJ, Ring C, Bosch JA, Drayson MT, Veldhuijzen van Zanten JJ. The time  course of the inflammatory response to the Salmonella typhi vaccination. Brain Behav Immun. 2013 Jan 16. [Epub ahead of print].

198. Paris B, Arahood T, Asche C, Amundson G. Voluntary reporting of health care  personnel seasonal influenza vaccination rates and the impact of universal policies in Illinois hospitals. Vaccine. 2013 Jan 7; 31(3):514-7.

199. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine. 2013 Jan 21; 31(5):728-31.

200. Paternina-Caicedo A, De la Hoz-Restrepo F, Gamboa-Garay O, Castañeda-Orjuela C, Velandia-González M, Alvis-Guzmán N. How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia. Vaccine. 2013 Jan 2;31(2):402-9.

201. Paulke-Korinek M, Kundi M, Laaber B, Brodtraeger N, Seidl-Friedrich C, Wiedermann U, Kollaritsch H. Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. Vaccine. 2013 Jan 7. [Epub ahead of print].

202. Pedrosa AF, Morais P, Nogueira A, Pardal J, Azevedo F. Sweet's syndrome triggered by pneumococcal vaccination. Cutan Ocul Toxicol. 2013 Jan 25. [Epub ahead of print]

203. Perkins RB, Tipton H, Shu E, Marquez C, Belizaire M, Porter C, Clark JA, Pierre-Joseph N. Attitudes Toward HPV Vaccination Among Low-Income and Minority Parents of Sons: A Qualitative Analysis. Clin Pediatr (Phila). 2013 Jan 29. [Epub ahead of print].

204. Perkins RB, Apte G, Marquez C, Porter C, Belizaire M, Clark JA, Pierre-Joseph N. Factors affecting human papillomavirus vaccine use among White,  Black and Latino parents of sons. Pediatr Infect Dis J. 2013 Jan; 32(1):e38-44.

205. Petousis-Harris H, Poole T, Stewart J, Turner N, Goodyear-Smith F, Coster G, Lennon D. An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: A randomized trial. Vaccine.  2013 Jan 8. [Epub  ahead of print].

206. Phillips CJ, Woolpert T, Sevick C, Faix D, Blair PJ, Crum-Cianflone NF. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US  military service members, 2006-2009. Clin Infect Dis. 2013 Jan; 56(1):11-9.

207. Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine. 2013 Jan 11. [Epub ahead of print].

208. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine. 2013 Jan 30; 31(6):927-42.

209. Pletz MW, van der Linden M, Fobiwe JP, Theilacker C. [Pneumococcal vaccination in adults - background of the current discussion]. Dtsch Med Wochenschr. 2013 Feb; 138(5):185-7.

210. Poli F, Overeem S, Lammers GJ, Plazzi G, Lecendreux M, Bassetti CL, Dauvilliers Y, Keene D, Khatami R, Li Y, Mayer G, Nohynek H, Pahud B, Paiva T, Partinen M, Scammell TE, Shimabukuro T, Sturkenboom M, van Dinther K, Wiznitzer M, Bonhoeffer J. Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine. 2013 Jan 30; 31(6):994-1007.

211. Postma MJ, Standaert BA. Economics of vaccines revisited. Hum Vaccin Immunother. 2013 Jan 30;9(5). [Epub ahead of print].

212. Prelog M, Almanzar G, Rieber N, Ottensmeier B, Zlamy M, Liese J. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents  after a whole cell (wcP) or aP primary vaccination. Vaccine. 2013 Jan 2; 31(2):387-93.

213. Principi N, Marchisio P, Terranova L, Zampiero A, Baggi E, Daleno C, Tirelli S, Pelucchi C, Esposito S. Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. Hum Vaccin Immunother. 2013 Jan 16; 9(5). [Epub ahead of print]

214. Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P,  Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K, Nguyen-Van-Tam J. Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine. PLoS  One. 2013; 8(1):e47448.

215. Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2013 Jan 7; 31(3):452-60.

216. Qian L, Tseng HF, Sy LS, Jacobsen SJ. Confounder adjustment in vaccine safety studies: Comparing three offset terms for case-centered approach. Vaccine. 2013 Jan 2;31(2):431-5.

217. Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, Shamshiri AR, Khairkhah M, Shekari Ebrahimabad H, Karimi A. Detection of Serum Antibodies against Measles, Mumps and Rubella after Primary Measles, Mumps and Rubella (MMR) Vaccination in Children. Arch Iran Med. 2013 Jan;16(1):38-41.

218. Ratanasiripong NT, Cheng AL, Enriquez M. What college women know, think, and do about human papillomavirus (HPV) and HPV vaccine. Vaccine. 2013 Jan 10. [Epub ahead of print].

219. Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, Garcia G, Fonseca M, Hung LH, Kahn AL, Burton A, Landaverde JM, Aylward RB. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013 Jan 31; 368(5):416-24.

220. Retrouvey M, Koch LH, Williams JV. Gianotti-crosti syndrome following childhood vaccinations. Pediatr Dermatol. 2013 Jan;30(1):137-8.

221. Robberstad B, Akselsen PE, Kværner KJ, Berstad AK. Response to "Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway". Vaccine. 2013 Jan 7;31(3):442-3.

222. Roberts L. Disease eradication. Killings force rethinking of Pakistan's anti-polio drive. Science. 2013 Jan 18;339(6117):259-60.

223. Roehr B. US vaccination schedule is safe and effective, says Institute of Medicine. BMJ. 2013 Jan 23;346:f516.

224. Ruiz-Palacios GM, Huang LM, Lin TY, Hernandez L, Guerrero ML, Villalobos AL, Van der Wielen M, Moreira M, Fissette L, Borys D, Miller JM. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J. 2013 Jan;32(1):62-71.

225. Saha A, Chowdhury MI, Nazim M, Alam MM, Ahmed T, Hossain MB, Hore SK, Sultana GN, Svennerholm AM, Qadri F. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area  in Bangladeshi children. Vaccine. 2013 Jan 11;31(4):647-52.

226. Salleras L, Navas E, Torner N, Prat AA, Garrido P, Soldevila N, Domínguez A. Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children. Hum Vaccin Immunother. 2013 Jan 7;9(3). [Epub ahead of print].

227. Sambhara D. A(H1N1)pdm09 vaccination of healthcare workers: Improved immune  responses in low responders following revaccination. J Infect Dis. 2013 Jan 10. [Epub ahead of print].

228. Sammon CJ, McGrogan A, Snowball J, de Vries CS. Pandemic influenza vaccination during pregnancy: An investigation of vaccine uptake during the 2009/10 pandemic vaccination campaign in Great Britain. Hum Vaccin Immunother. 2013 Jan 30; 9(4). [Epub ahead of print]

229. Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens  A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H. PER.C6(®) cells  as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated  poliovirus vaccine. Vaccine. 2013 Jan 21; 31(5):850-6.

230. Sarnquist C, Sawyer M, Calvin K, Mason W, Blumberg D, Luther J, Maldonado Y. Communicating about vaccines and vaccine safety: what are medical residents learning and what do they want to learn? J Public Health Manag Pract. 2013 Jan-Feb;19(1):40-6.

231. Schmidt S, Saulle R, Di Thiene D, Boccia A, La Torre G. Do the quality of the trials and the year of publication affect the efficacy of intervention to improve seasonal influenza vaccination among healthcare workers? Results of a systematic review. Hum Vaccin Immunother. 2013 Jan 4; 9(2). [Epub ahead of print].

232. Schultz JD, Douglas H, Haselow D. A new immunization information system: Introducing Arkansas WebIZ. J Ark Med Soc. 2013 Jan; 109(8):156-7.

233. Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine  administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine. 2013 Jan 2; 31(2):291-4.

234. Schütz K, Hughes RG, Parker A, Quinti I, Thon V, Cavaliere M, Würfel M, Herzog W, Gessner JE, Baumann U. Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects. J Clin Immunol. 2013 Jan; 33(1):288-96.

235. Shankar AG, Lee A, Reddy H, Seymour M. Bordetella pertussis infection in a child with completed primary immunization: A case report. Hum Vaccin Immunother.  2013 Jan 4; 9(2). [Epub ahead of print]

236. Shaw AR. Human papillomavirus vaccines six years after approval. Annu Rev Med. 2013 Jan 14;64:91-100.

237. Shen AK, Bridges CB, Tan L. The first national adult immunization summit 2012: Implementing change through action. Vaccine. 2013 Jan 2;31(2):279-84.

238. Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; On behalf of the 3012 study group. 13-Valent  pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial. Vaccine. 2013 Jan 7. [Epub ahead of print].

239. Simpson JE, Hills RA, Allwes D, Rasmussen L. Uptake of meningococcal vaccine in Arizona schoolchildren after implementation of school-entry immunization requirements. Public Health Rep. 2013 Jan;128(1):37-45.

240. Singal A, Sonthalia S, Pandhi D. Ulcerated lupus vulgaris at the site of bacille calmette-guérin vaccination. Pediatr Dermatol. 2013 Jan; 30(1):147-8.

241. Singh Joy SD. Shingles Vaccine may be Safe in People with Immune-Mediated Disease. Am J Nurs. 2013 Jan; 113(1):58.

242. Small SL, Sampselle CM, Martyn KK, Dempsey AF. Using risk to target HPV vaccines in high-risk, low-resource organizations. Hum Vaccin Immunother. 2013 Jan 16; 9(5). [Epub ahead of print]

243. Soares AP, Kwong Chung CK, Choice T, Hughes EJ, Jacobs G, van Rensburg EJ, Khomba G, de Kock M, Lerumo L, Makhethe L, Maneli MH, Pienaar B, Smit E, Tena-Coki NG, van Wyk L, Boom WH, Kaplan G, Scriba TJ, Hanekom WA. Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns. J Infect Dis. 2013 Jan 28. [Epub ahead of print].

244. Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Choi WS, Lee J, Jeong HW, Kee SY, Kim WJ. Long-term Immunogenicity of Pandemic Influenza A/H1N1 2009 Vaccine Among Healthcare Workers: Seasonal Vaccine Recipients Versus Non-recipients. Clin Vaccine Immunol. 2013 Jan 30. [Epub ahead of print].

245. Spencer Nee Pilkington AM, Brabin L, Verma A, Roberts SA. Mothers' screening histories influence daughters' vaccination uptake: An analysis of linked cervical screening and human papillomavirus vaccination records in the North West of England. Eur J Cancer. 2013 Jan 2. [Epub ahead of print].

246. Standaert B, Gomez JA, Raes M, Debrus S, Velázquez FR, Postma MJ. Impact of rotavirus vaccination on hospitalisations in belgium: comparing model predictions with observed data. PLoS One. 2013;8(1):e53864.

247. Stewart AM, Cox MA. State law and influenza vaccination of health care personnel. Vaccine. 2013 Jan 21; 31(5):827-32.

248. Straßburg HM. [Vaccinations ethics and health care]. Klin Padiatr. 2013 Jan; 225(1):1-2.

249. Struijka GH, Bouts AH, Rijkers GT, Kuin EA, Ten Berge IJ, Bemelman FJ. Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination. Am J Transplant. 2013 Jan 7. [Epub ahead of print].

250. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL. Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines. J Infect Dis. 2013 Jan 16. [Epub ahead of print].

251. Suzuki M, Yoshimine H, Harada Y, Tsuchiya N, Shimada I, Ariyoshi K, Inoue K. Estimating the Influenza Vaccine Effectiveness against Medically Attended Influenza in Clinical Settings: A Hospital-Based Case-Control Study with a Rapid  Diagnostic Test in Japan. PLoS One. 2013;8(1):e52103.

252. Tacken MA, Jansen B, Mulder J, Visscher S, Heijnen ML, Campbell SM, Braspenning JC. Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: A cohort study from 2009 to 2011. Vaccine. 2013 Jan 30; 31(6):900-5.

253. Taha SA, Matheson K, Anisman H. The 2009 H1N1 Influenza Pandemic: The Role of Threat, Coping, and Media Trust on Vaccination Intentions in Canada. J Health  Commun. 2013 Jan 10. [Epub ahead of print].

254. Talaat KR, Karron RA, Liang PH, McMahon BA, Luke CJ, Thumar B, Chen GL, Min  JY, Lamirande EW, Jin H, Coelingh KL, Kemble GW, Subbarao K. An open-label phase  I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respi Viruses. 2013 Jan; 7(1):66-73.

255. Talbot TR, Talbot HK. Influenza Prevention Update: Examining Common Arguments Against Influenza Vaccination. JAMA. 2013 Jan 18:1-2. [Epub ahead of print].

256. Tapia-Conyer R, Betancourt-Cravioto M, Saucedo-Martínez R, Motta-Murguía L,  Gallardo-Rincón H. Strengthening vaccination policies in Latin America: An evidence-based approach. Vaccine. 2013 Jan 25. [Epub ahead of print].

257. Tavares F, Cheuvart B, Heineman T, Arellano F, Dubin G. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine. 2013 Jan 10. [Epub ahead of print].

258. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults. Am J Trop Med Hyg. 2013 Jan; 88(1):73-88. 

259. Tompkins DM, Buddle BM, Whitford J, Cross ML, Yates GF, Lambeth MR, Nugent G. Sustained protection against tuberculosis conferred to a wildlife host by single dose oral vaccination. Vaccine. 2013 Jan 30; 31(6):893-9.

260. Torner N, Anton A, Barrabeig I, Lafuente S, Parron I, Arias C, Camps N, Costa J, Martínez A, Torra R, Godoy P, Minguell S, Ferrús G, Cabezas C, Domínguez A, Of Catalonia Spain TM. Epidemiology of two large measles virus outbreaks in Catalonia: What a difference the month of administration of the first dose of vaccine makes. Hum Vaccin Immunother. 2013 Jan 9; 9(3). [Epub ahead of print].

261. Traynor K. FDA approves first cell-based seasonal flu vaccine. Am J Health Syst Pharm. 2013 Jan 1; 70(1):8.

262. Tu HA, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model". BMC Infect Dis. 2013 Jan 30; 13(1):54. [Epub ahead of print].

263. Tuite AR, Fisman DN. Number-needed-to-vaccinate calculations: Fallacies associated with exclusion of transmission. Vaccine. 2013 Jan 30; 31(6):973-8.

264. Ubale RV, D'Souza MJ, Infield DT, McCarty NA, Zughaier SM. Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition. J Microencapsul. 2013;30(1):28-41.

265. Upreti SR, Janusz K, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, Shrestha MM, Sedai TR, Fischer M, Gibbons RV, Shrestha S, Hills SL. Estimation of the Impact of a Japanese Encephalitis Immunization Program with Live, Attenuated  SA 14-14-2 Vaccine in Nepal. Am J Trop Med Hyg. 2013 Jan 28. [Epub ahead of print].

266. Valour F, Bénet T, Chidiac C; for the study group. Pandemic A(H1N1)2009 influenza vaccination in Lyon University Hospitals, France: Perception and attitudes of hospital workers. Vaccine. 2013 Jan 11; 31(4):592-595.

267. van de Waterbeemd B, Zomer G, van den Ijssel J, van Keulen L, Eppink MH, van der Ley P, van der Pol LA. Cysteine Depletion Causes Oxidative Stress and Triggers Outer Membrane Vesicle Release by Neisseria meningitidis; Implications for Vaccine Development. PLoS One. 2013;8(1):e54314.

268. van der Sande MA, Jacobi A, Meijer A, Wallinga J, van der Hoek W, van der Lubben M. The 2009 influenza A (H1N1) pandemic : Management and vaccination strategies in The Netherlands. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jan; 56(1):67-75.

269. Van Ermen A, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O. Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail. 2013 Jan 4. [Epub ahead of print] PubMed PMID:

270. Van Malderen C, Ogali I, Khasakhala A, Muchiri SN, Sparks C, Van Oyen H, Speybroeck N. Decomposing Kenyan socio-economic inequalities in skilled birth attendance and measles immunization. Int J Equity Health. 2013 Jan 7; 12(1):3.

271. Van Vlaenderen I, Van Bellinghen LA, Meier G, Poulsen Nautrup B. An approximation of herd effect due to vaccinating children against seasonal influenza -- a potential solution to the incorporation of indirect effects into static models. BMC Infect Dis. 2013 Jan 22; 13(1):25. [Epub ahead of print].

272. Vanguri V, Govern CC, Smith R, Huseby ES. Viral antigen density and confinement time regulate the reactivity pattern of CD4 T-cell responses to vaccinia virus infection. Proc Natl Acad Sci U S A. 2013 Jan 2; 110(1):288-93.

273. Varma C, Kalyan CK. Haemophilus influenzae type b vaccination in India-a reality check. Int J Infect Dis. 2013 Jan; 17(1):e69.

274. Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother. 2013 Jan 14; 9(4). [Epub ahead of print].

275. Viaris de Lesegno B, Beucher G, Lamendour N, D'Alché-Gautier MJ, Dreyfus M,  Benoist G. [Continuous medical evaluation of the prevention of fetomaternal rhesus-D allo-immunization.]. J Gynecol Obstet Biol Reprod (Paris). 2013 Jan 11.  [Epub ahead of print].

276. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, Iii ES, Xu  W, Shi L, Kukreti V, Crump M, Kuruvilla J. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leuk Lymphoma. 2013 Jan 8. [Epub ahead of print].

277. von Kries R. [Vaccination ethics: report on a workshop at the ruher-universität bochum]. Klin Padiatr. 2013 Jan; 225(1):50-2.

278. Wakadha H, Chandir S, Were EV, Rubin A, Obor D, Levine OS, Gibson DG, Odhiambo F, Laserson KF, Feikin DR. The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya. Vaccine. 2013 Jan 30; 31(6):987-93.

279. Walson PD, Halvorsen M, Edge J, Casavant MJ, Kelley MT. Pharmacokinetic Comparison of Acetaminophen Elixir Versus Suppositories in Vaccinated Infants (Aged 3 to 36 Months): A Single-Dose, Open-Label, Randomized, Parallel-Group Design. Clin Ther. 2013 Jan 22. [Epub ahead of print].

280. Wang CC, Zhu B, Fan X, Gicquel B, Zhang Y. Systems Approach to Tuberculosis  Vaccine Development. Respirology. 2013 Jan 18. [Epub ahead of print].

281. Wang IK, Lin CL, Chang YC, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Huang CC, Sung FC. Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine. 2013 Jan 11; 31(4):718-24.

282. Wang S, Chen J, Zhang Y, Diao N, Zhang S, Wu J, Lu C, Wang F, Gao Y, Shao L, Jin J, Weng X, Zhang W. Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals. Clin Vaccine Immunol. 2013 Jan; 20(1):69-76.

283. Ward K, Dey A, Hull B, Quinn HE, Macartney K, Menzies R. Evaluation of Australia's varicella vaccination program for children and adolescents. Vaccine.  2013 Jan 2. [Epub  ahead of print].

284. Weiss WM, Rahman MH, Solomon R, Ward D. Determinants of performance of supplemental immunization activities for polio eradication in Uttar Pradesh, India: social mobilization activities of the Social mobilization Network (SM Net) and Core Group Polio Project (CGPP). BMC Infect Dis. 2013 Jan 17; 13(1):17. [Epub  ahead of print].

285. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Cost-effectiveness of adult pneumococcal vaccination: Response to Grabenstein et al. Vaccine. 2013 Jan 11. [Epub ahead of print].

286. Whelan PJ, Walwyn R, Gaughran F, Macdonald A. Impact of the demand for 'proxy assent' on recruitment to a randomised controlled trial of vaccination testing in care homes. J Med Ethics. 2013 Jan; 39(1):36-40.

287. Whitney CG. More evidence for use of pneumococcal conjugate vaccines. Lancet. 2013 Jan 19; 381(9862):182-3.

288. Wilson K, Ducharme R, Hawken S. Association between socioeconomic status and adverse events following immunization at 2, 4, 6 and 12 months. Hum Vaccin Immunother. 2013 Jan 17; 9(5). [Epub ahead of print].

289. Wilson SE, Harris T, Sethi P, Fediurek J, Macdonald L, Deeks SL. Coverage from Ontario, Canada's school-based HPV vaccine program: The first three years. Vaccine. 2013 Jan 21;31(5):757-62.

290. Wynn JL, Li L, Cotten CM, Phelps DL, Shankaran S, Goldberg RN, Carlo WA, Van Meurs K, Das A, Vohr BR, Higgins RD, Stoll BJ, D'Angio CT. Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants. J Perinatol. 2013 Jan 31. [Epub ahead of print].

291. Wójcik OP, Simonsen J, Mølbak K, Valentiner-Branth P. Validation of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish childhood vaccination database. Vaccine. 2013 Jan 30; 31(6):955-9.

292. Xu S, Hambidge SJ, McClure DL, Daley MF, Glanz JM. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled  case series design. Stat Med. 2013 Jan 10. [Epub ahead of print].

293. Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ; the ‘Public Health Agency of Canada'/‘Canadian Institute of Health Research' Influenza Research Network (PCIRN) Rapid Trial study #3 (RT-03) investigators. Unusual patterns of IgG avidity in some young children following two doses of adjuvanted  pandemic H1N1(2009) influenza vaccine. Clin Vaccine Immunol. 2013 Jan 23. [Epub ahead of print].

294. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health. 2013 Jan;103(1):164-9.

295. Yu Q, Zhu L, Kang H, Yang Q. Mucosal Lactobacillus vectored vaccines. Hum Vaccin Immunother. 2013 Jan 15; 9(4). [Epub ahead of print].

296. Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY,  Li JX, Gao F, Chen QH, Zhu QY, Chu K, Wu X, Yao X, Guo HJ, Chen XQ, Liu P, Dong YY, Li FX, Shen XL, Wang JZ. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013 Jan 23. [Epub ahead of print].

297. Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax(®)) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip(®)) to adults aged ≥60 years: An open-label, randomised trial. Vaccine. 2013 Jan 10. [Epub ahead of print].

298. Zuniga A, Liniger M, Morin TN, Marty RR, Wiegand M, Ilter O, Weibel S, Billeter MA, Knuchel MC, Naim HY. Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother. 2013 Jan 16; 9(3). [Epub ahead of print].

[top